Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study The GeparSepto trial ...

Final survival results from the WSG ADAPT hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) chemotherapy trial demonstrated that weekly nanoparticle ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database A safety cohort ...

(RTTNews) - Corcept Therapeutics Incorporated (CORT), Monday announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in ...

Please provide your email address to receive an email when new articles are posted on . In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

Immuneering (NASDAQ:IMRX) provided an update from its ongoing Phase 2A trial of atebumetanib plus modified gemcitabine and ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...

To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel has been observed to be well tolerated. The study included one Complete Response out of ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and ...